Vol. 7, Issue - 1, Part A (2023)

2023, Vol. 7 Issue 1, Part APages: 46-51

The efficacy and safety of a Unani pharmacopoeal formulations-raughan kahu in Sahar (Insomnia): A preliminary study

Parvez Khan, Radhey Shyam Verma, Sadia Ayub, Sheereen Afza, Jamal Akhtar and Asim Ali Khan
Viewed: 273  -  Downloaded: 91
Abstract:
In demographical studied, Out of 100 patients of Sahar (Insomnia), 35 (35.00%) were male and 65 (65.00%) female and female have higher incidence than male. The greater incidence of duration of the disease observed in 73 (73.00%) is 7-days-3 month than 34 (34.00%) 6-months to 2 years. Higher incidence of average social status patients had been observed 73 (73.00%) than poor 20 (20.00%) followed by good social status 07 (7.00%). Greater incidence of non-vegetarian 91 (91.00%) patients had been observed than vegetarian 09 (9.00%) (Table-1). Middle income group had more incidence of Sahar (Insomnia) 65 (65.00%) than lower income group 31 (31.00%) followed by higher income group 04 (4.00%) (Table-1). Non-smoker patients had more incidences 97 (97.00%) than smokers 03 (3.00%). Non-chewing habit Patient had more incidence 97 (97.00%) than chewing 03 (3.00%). According to present history patients who had difficulty in sleep had more incidences 69 (69.00%) than staying sleep 11 (11.00%) patients. Past history of patients of no history had more incidence 92 (92.00%) than constipation and indigestion and hypertension 02 (2.00%) followed by Insomnia, difficulty in sleep and khafkhan 01 (1.00%) patients. The higher incidence of temperament was found more in Balghami (Phlegmatic) temperament patients 94 (94.00%) than Damavi (Sanguine) 05 (5.00%) followed by safravi (bilious) 01 (1.00%) (Table-1). In Clinical assessment Insomnia Severity Index (ISI), when Unani pharmacopeial formulation Raughan Kahu (liquid oil) was locally applied (1.0 ml/day) to the patients for a period of 7-days. A significant reduction 27.11% (p<0.0001) in Insomnia Severity Index (ISI) had been observed, when compared with baseline to post-treatment (7-days) (Table-2). In biochemical study, No significant alterations in liver function tests and kidney function tests had been observed. Therefore, it can be inferred that it did not induce any negative or unfavorable response. The safety of the drug is therefore conformed (Table-3). In haematological study, no significant alterations in the level of haemoglobin, Red blood corpuscles (RBC), Total Leucocytes counts (TLC), Erythrocyte Sedimentation Rate (ESR) and Differential Leucocytes Counts (DLC) had been observed. When compared with the values of baseline and Post-treatment (7-days) (Table-4).
How to cite this article:
Parvez Khan, Radhey Shyam Verma, Sadia Ayub, Sheereen Afza, Jamal Akhtar, Asim Ali Khan. The efficacy and safety of a Unani pharmacopoeal formulations-raughan kahu in Sahar (Insomnia): A preliminary study. Int J Unani Integ Med 2023;7(1):46-51. DOI: 10.33545/2616454X.2023.v7.i1a.230
International Journal of Unani and Integrative Medicine

International Journal of Unani and Integrative Medicine

 
International Journal of Unani and Integrative Medicine
Call for book chapter